These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31858338)

  • 21. A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis.
    Chung L; Fiorentino D
    J Am Acad Dermatol; 2006 May; 54(5):880-2. PubMed ID: 16635673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy.
    Di Battista M; Della Rossa A; Mosca M
    J Rheumatol; 2024 Sep; 51(9):899-903. PubMed ID: 38879188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Hughes M; Allanore Y; Chung L; Pauling JD; Denton CP; Matucci-Cerinic M
    Nat Rev Rheumatol; 2020 Apr; 16(4):208-221. PubMed ID: 32099191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treprostinil Hydrogel Iontophoresis in Systemic Sclerosis-Related Digital Skin Ulcers: A Safety Study.
    Guigui A; Mazet R; Blaise S; Cracowski C; Beau-Guillaumot M; Kotzki S; Roustit M; Cracowski JL
    J Clin Pharmacol; 2020 Jun; 60(6):758-767. PubMed ID: 32080862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials.
    Khanna D; Denton CP; Merkel PA; Krieg T; Le Brun FO; Marr A; Papadakis K; Pope J; Matucci-Cerinic M; Furst DE; ;
    JAMA; 2016 May; 315(18):1975-88. PubMed ID: 27163986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of Raynaud's phenomenon and digital ischemia.
    Herrick AL
    Curr Rheumatol Rep; 2013 Jan; 15(1):303. PubMed ID: 23292819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany].
    Juche A; Siegert E; Mueller-Ladner U; Riemekasten G; Günther C; Kötter I; Henes J; Blank N; Voll RE; Ehrchen J; Schmalzing M; Susok L; Schmeiser T; Sunderkoetter C; Distler J; Worm M; Kreuter A; Horváth ON; Schön MP; Korsten P; Zeidler G; Pfeiffer C; Krieg T; Hunzelmann N; Moinzadeh P
    Z Rheumatol; 2020 Dec; 79(10):1057-1066. PubMed ID: 32040755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis.
    Avouac J; Meune C; Ruiz B; Couraud PO; Uzan G; Boileau C; Kahan A; Chiocchia G; Allanore Y
    Ann Rheum Dis; 2012 Mar; 71(3):394-9. PubMed ID: 22085793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis.
    Di Battista M; Della Rossa A; Da Rio M; De Mattia G; Morganti R; Mosca M
    J Rheumatol; 2023 Aug; 50(8):1029-1031. PubMed ID: 37003608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
    Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER
    Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients.
    Silva I; Teixeira A; Oliveira J; Almeida I; Almeida R; Vasconcelos C
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S127-30. PubMed ID: 26242908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
    Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
    Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.
    Rosato E; Borghese F; Pisarri S; Salsano F
    Clin Rheumatol; 2009 Dec; 28(12):1379-84. PubMed ID: 19690939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment.
    Frech TM; Machin DR; Murtaugh MA; Stoddard GJ; Bloom SI; Phibbs JV; Donato AJ
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):175-182. PubMed ID: 30277867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis.
    Botzoris V; Drosos AA
    Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.